Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nugent, A. G.
Right arrow Articles by Johnston, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nugent, A. G.
Right arrow Articles by Johnston, G. D.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 45, Issue 1 105-107, Copyright © 1996 by American Diabetes Association


ARTICLES

Impaired vasoconstriction to endothelin 1 in patients with NIDDM

AG Nugent, C McGurk, JR Hayes and GD Johnston
Department of Therapeutics and Pharmacology, Queens University of Belfast, Northern Ireland.

Microvascular disease is an important cause of morbidity in diabetes. There is evidence that impaired autoregulation of blood flow is involved in the pathogenesis of diabetic microangiopathy. The vascular endothelium plays a central role in the regulation of vascular tone. Endothelin (ET)-1 is a potent endothelium-derived vasoconstrictor substance that contributes to basal vascular tone. Impaired vasoconstriction in response to endogenous ET could result in hyperperfusion and subsequent microvascular damage. The purpose of our study was to determine whether vascular responses to locally administered ET-1 are impaired in NIDDM. Nine patients with NIDDM and 12 control subjects underwent cannulation of the nondominant brachial artery. Forearm blood flow (FBF) was measured at baseline and during the drug infusion using strain-gauge venous occlusion plethysmography. ET-1 (5 pmol/min) was infused for 60 min at a rate of 1 ml/min. FBF was measured during the first 5 min of the infusion and at 5-min intervals thereafter. Results were expressed as change in FBF from baseline (ml.100 ml-1.min-1) and were analyzed using repeated measures analysis of variance and Dunnett's test of multiple comparisons. Control subjects showed a gradual onset of vasoconstriction in response to ET-1, which reached maximum at 35 min (1.1 ml.100 ml-1.min-1; P < 0.01). There was no reduction in FBF in response to ET-1 in the diabetic group. The differences between the diabetic and control groups were significant (P < 0.03). In conclusion, ET-1 infused locally at 5 pmol/min does not cause vasoconstriction in patients with NIDDM.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. J. Padilla, P. McDonough, B. J. Behnke, Y. Kano, K. S. Hageman, T. I. Musch, and D. C. Poole
Effects of Type II diabetes on capillary hemodynamics in skeletal muscle
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2439 - H2444.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. V. G. Katakam, J. A. Snipes, C. D. Tulbert, K. Mayanagi, A. W. Miller, and D. W. Busija
Impaired endothelin-induced vasoconstriction in coronary arteries of Zucker obese rats is associated with uncoupling of [Ca2+]i signaling
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R145 - R153.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
K. Sharma, L. Deelman, M. Madesh, B. Kurz, E. Ciccone, S. Siva, T. Hu, Y. Zhu, L. Wang, R. Henning, et al.
Involvement of transforming growth factor-{beta} in regulation of calcium transients in diabetic vascular smooth muscle cells
Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1258 - F1270.
[Abstract] [Full Text]


Home page
CirculationHome page
M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
Circulation, September 23, 2003; 108(12): 1527 - 1532.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Hua, S. Munk, H. Goldberg, I. G. Fantus, and C. I. Whiteside
High Glucose-suppressed Endothelin-1 Ca2+ Signaling via NADPH Oxidase and Diacylglycerol-sensitive Protein Kinase C Isozymes in Mesangial Cells
J. Biol. Chem., September 5, 2003; 278(36): 33951 - 33962.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Ihlemann, C. Rask-Madsen, A. Perner, H. Dominguez, T. Hermann, L. Kober, and C. Torp-Pedersen
Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H875 - H882.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
J. A. Beckman, M. A. Creager, and P. Libby
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
JAMA, May 15, 2002; 287(19): 2570 - 2581.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Perera, J.R. Petrie, C. Hillier, M. Small, N. Sattar, J.M.C. Connell, and M.A. Lumsden
Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes
Hum. Reprod., February 1, 2002; 17(2): 497 - 502.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis
Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4666 - 4673.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. S. Chung, A. Harris, P. J. Halter, L. Kagemann, E. J. Roff, H. J. Garzozi, S. L. Hosking, and B. J. Martin
Regional Differences in Retinal Vascular Reactivity
Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2448 - 2453.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Sakthivel, J.-C. Zhang, D. K. Strickland, M. Gafvels, and K. R. McCrae
Regulation of the Ligand Binding Activity of the Human Very Low Density Lipoprotein Receptor by Protein Kinase C-dependent Phosphorylation
J. Biol. Chem., January 5, 2001; 276(1): 555 - 562.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
J. A. Beckman, A. B. Goldfine, M. B. Gordon, L. A. Garrett, and M. A. Creager
Inhibition of Protein Kinase C{beta} Prevents Impaired Endothelium-Dependent Vasodilation Caused by Hyperglycemia in Humans
Circ. Res., January 11, 2002; 90(1): 107 - 111.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1996 by the American Diabetes Association.